Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.326 - Six Cases of Adult-Onset PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Cervical Adenopathy) Syndrome
D1.327 - A Rare Primary Immunodeficency Hidden in Autoimmunity: Heterozygote CD3G variant in a 49-year-old Female Patient
D1.332 - Hereditary Angioedema in Ukraine
D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach
D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia
D1.335 - TeloNet is born; why immunologists should know about telomere disorders
D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)
D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
Download the app
The congress at your fingertips
Available on
Download